



(51) International Patent Classification:

C07D 413/14 (2006.01) A61P 37/00 (2006.01)

C07D 413/12 (2006.01) A61K 31/553 (2006.01)

(21) International Application Number:

PCT/US2020/049487

(22) International Filing Date:

04 September 2020 (04.09.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/897,223 06 September 2019 (06.09.2019) US

62/932,404 07 November 2019 (07.11.2019) US

63/001,016 27 March 2020 (27.03.2020) US

63/004,319 02 April 2020 (02.04.2020) SR

63/004,290 02 April 2020 (02.04.2020) US

63/004,301 02 April 2020 (02.04.2020) US

(71) Applicant (for all designated States except US): RIGEL

PHARMACEUTICALS, INC. [US/US]; 1180 Veterans

Boulevard, South San Francisco, California 94080 (US).

(72) Inventors; and

(71) Applicants (for US only): CHEN, Yan [US/US]; c/o Rigel

Pharmaceuticals, Inc., 1180 Veterans Boulevard, South San

Francisco, California 94080 (US). YU, Jiaxin [US/US]; c/o

Rigel Pharmaceuticals, Inc., 1180 Veterans Boulevard,

South San Francisco, California 94080 (US). SHAW, Si-

mon [US/US]; c/o Rigel Pharmaceuticals, Inc., 1180 Veter-

ans Boulevard, South San Francisco, California 94080 (US).

DARWISH, Ihab [US/US]; c/o Rigel Pharmaceuticals,

Inc., 1180 Veterans Boulevard, South San Francisco, Cali-

fornia 94080 (US). TAYLOR, Vanessa [GB/US]; c/o Rigel

Pharmaceuticals, Inc., 1180 Veterans Boulevard, South San

Francisco, California 94080 (US). BHAMIDIPATI, So-

masekhar [US/US]; c/o Rigel Pharmaceuticals, Inc., 1180

Veterans Boulevard, South San Francisco, California 94080

(US). LUO, Zhushou [IN/US]; c/o Rigel Pharmaceuticals,

Inc., 1180 Veterans Boulevard, South San Francisco, Cali-

fornia 94080 (US). KOLLURI, Rao [CN/US]; c/o Rigel

Pharmaceuticals, Inc., 1180 Veterans Boulevard, South San

Francisco, California 94080 (US).

(74) Agent: SLATER, Stacey C. et al.; Klarquist, One World

Trade Center, Suite 1600, 121 SW Salmon Street, Portland,

Oregon 97204 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,

AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: RIPI INHIBITORY COMPOUNDS AND METHODS FOR MAKING AND USING THE SAME

(57) Abstract: Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed compounds, pharmaceutical compositions, and/or combinations may be used to treat or prevent a kinase-associated disease or condition, particularly a RIP1-associated disease or condition.



WO 2021/046407 A1